Abstract

Objective:To investigate the expression of Nrf2 and Keap1 in nasopharyngeal carcinoma (NPC) and to analyze the relationship between the expression of Nrf2 and Keap1 and the clinicopathological features and prognosis of patients with nasopharyngeal carcinoma. Method:A total of 108 patients with biopsy-proven nonkeratinizing squamous cell carcinoma-undifferentiated type with available biopsy specimens for tissue microarray (TMA) construction were selected. The relationship between Nrf2 and Keap1 protein expression and the prognosis of radiotherapy in patients with nasopharyngeal carcinoma was analyzed. Result: The overall 5-year disease free survival (DFS) and overall survival(OS) rates were 57.4% and 70.2%, respectively. The 5-year DFS rate was 59.4% in the low nuclear Nrf2 expression group, and 53.8% in the high nuclear Nrf2 expression group. The 5-year DFS rate was 42.2% in the low cytoplasmic Keap1 expression group, and 68.2% in the high cytoplasmic Keap1 expression group. The 5-year OS rate was 70.8% in the low nuclear Nrf2 expression group, and 69.2% in the high nuclear Nrf2 expression group. The 5-year OS rate was 55.6% in the low cytoplasmic Keap1 expression group, and 80.9% in the high cytoplasmic Keap1 expression group.Conclusion:We found that nuclear Nrf2 or cytoplasmic Keap1 expression had no significant association with clinicopathological features. The high expression of cytoplasmic Keap1 had higher DFS and OS. Keap1 is an independent prognostic factor for DFS and OS in NPC patient.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.